ScreenerHero

IMNMImmunome, Inc.

NAS · US · Healthcare · Biotechnology · immunome.com
28.52USD-4.38%Mkt Cap: 3.24B $P/E: —

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company d…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.24B $
Enterprise Value2.67B $
Revenue (TTM)0 $
Gross Profit-206.23M $
Net Income (TTM)-212.39M $
Revenue/Share0.0000 USD
Last Price28.52 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees247
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.33
PEG—
EV/EBITDA-10.38
EV/Revenue—
P/SInfinity
P/B6.06
EPS (TTM)-2.38
EPS (Forward)-2.48
52W Range
8.66593% of range30.06
52W High30.06 USD
52W Low8.665 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-3059.99%
ROE-33.48%
ROA-31.09%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-190.92M $
CapEx (TTM)15.93M $
FCF Margin—
FCF Yield-4.43%
Net Debt-515.26M $
Net Debt/EBITDA2.00
Balance Sheet
Debt/Equity0.01
Current Ratio15.08
Quick Ratio14.64
Book Value/Sh4.630 USD
Cash/Share4.578 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.31 USD
Upside (mean)+27.3%
Target Range30.00 USD – 40.00 USD
$30.00+27.3% to mean$40.00
# Analysts13
Ownership
Shares Out.113.58M
Float108.65M
Insiders6.58%
Institutions106.93%
Short Interest
Short Ratio14.9d
Short % Float18.57%
Short % Out.15.88%
Shares Short17.98M
Short (prev mo.)17.37M
Technical
SMA 5022.87 (+24.7%)
SMA 20021.70 (+31.5%)
Beta2.12
S&P 52W Chg18.16%
Avg Vol (30d)1.03M
Avg Vol (10d)1.24M
Technical Indicators
RSI (14)66.1
MACD1.6282
MACD Signal1.2877
MACD Hist.+0.3405
BB Upper29.77 USD
BB Middle25.14 USD
BB Lower20.51 USD
BB Width36.84%
ATR (14)1.491 USD
Vol Ratio (20d)0.79x